HLB Co., Ltd. (028300.KQ)
KRW 70500.0
(-1.26%)
KRW 70500.0
(-1.26%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 42.9 Billion KRW | -76.13% |
| 2022 | 179.7 Billion KRW | 157.37% |
| 2021 | 69.82 Billion KRW | 24.3% |
| 2020 | 56.17 Billion KRW | 46.22% |
| 2019 | 38.42 Billion KRW | 6.18% |
| 2018 | 36.18 Billion KRW | 57.28% |
| 2017 | 23 Billion KRW | -23.66% |
| 2016 | 30.13 Billion KRW | -21.64% |
| 2015 | 38.46 Billion KRW | 3.43% |
| 2014 | 37.18 Billion KRW | 78.71% |
| 2013 | 20.8 Billion KRW | -59.71% |
| 2012 | 51.64 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 14.79 Billion KRW | 32.64% |
| 2024 Q1 | 11.15 Billion KRW | 23.64% |
| 2023 Q4 | 9.02 Billion KRW | -7.28% |
| 2023 Q2 | 4.33 Billion KRW | -78.14% |
| 2023 Q1 | 19.81 Billion KRW | -38.86% |
| 2023 Q3 | 9.72 Billion KRW | 124.6% |
| 2023 FY | 42.9 Billion KRW | -76.13% |
| 2022 Q3 | 23.98 Billion KRW | -58.49% |
| 2022 Q4 | 32.41 Billion KRW | 35.12% |
| 2022 Q2 | 57.79 Billion KRW | -11.79% |
| 2022 Q1 | 65.51 Billion KRW | 49.81% |
| 2022 FY | 179.7 Billion KRW | 157.37% |
| 2021 Q2 | 8.39 Billion KRW | 10.96% |
| 2021 Q4 | 43.73 Billion KRW | 331.34% |
| 2021 Q3 | 10.13 Billion KRW | 20.79% |
| 2021 FY | 69.82 Billion KRW | 24.3% |
| 2021 Q1 | 7.56 Billion KRW | -66.79% |
| 2020 Q4 | 22.77 Billion KRW | 100.06% |
| 2020 FY | 56.17 Billion KRW | 46.22% |
| 2020 Q2 | 9.99 Billion KRW | -16.88% |
| 2020 Q1 | 12.02 Billion KRW | -4.59% |
| 2020 Q3 | 11.38 Billion KRW | 13.92% |
| 2019 Q2 | 9.52 Billion KRW | 33.39% |
| 2019 FY | 38.42 Billion KRW | 6.18% |
| 2019 Q4 | 12.6 Billion KRW | 37.75% |
| 2019 Q3 | 9.14 Billion KRW | -3.99% |
| 2019 Q1 | 7.14 Billion KRW | -37.79% |
| 2018 Q4 | 11.48 Billion KRW | 55.76% |
| 2018 FY | 36.18 Billion KRW | 57.28% |
| 2018 Q2 | 11.23 Billion KRW | 84.31% |
| 2018 Q1 | 6.09 Billion KRW | 21.34% |
| 2018 Q3 | 7.37 Billion KRW | -34.4% |
| 2017 Q1 | 5.96 Billion KRW | -4.27% |
| 2017 FY | 23 Billion KRW | -23.66% |
| 2017 Q4 | 5.02 Billion KRW | 1.77% |
| 2017 Q3 | 4.93 Billion KRW | -30.31% |
| 2017 Q2 | 7.08 Billion KRW | 18.84% |
| 2016 FY | 30.13 Billion KRW | -21.64% |
| 2016 Q4 | 6.22 Billion KRW | -4.83% |
| 2016 Q3 | 6.54 Billion KRW | -19.81% |
| 2016 Q2 | 8.15 Billion KRW | -11.38% |
| 2016 Q1 | 9.2 Billion KRW | -17.07% |
| 2015 Q1 | 9.08 Billion KRW | -27.82% |
| 2015 Q4 | 11.1 Billion KRW | 25.22% |
| 2015 Q3 | 8.86 Billion KRW | -5.76% |
| 2015 Q2 | 9.4 Billion KRW | 3.61% |
| 2015 FY | 38.46 Billion KRW | 3.43% |
| 2014 Q2 | 8.03 Billion KRW | 7.5% |
| 2014 Q4 | 12.58 Billion KRW | 38.3% |
| 2014 Q1 | 7.47 Billion KRW | 248.29% |
| 2014 FY | 37.18 Billion KRW | 78.71% |
| 2014 Q3 | 9.09 Billion KRW | 13.24% |
| 2013 Q1 | 7.71 Billion KRW | -32.88% |
| 2013 Q3 | 10.05 Billion KRW | 24.53% |
| 2013 FY | 20.8 Billion KRW | -59.71% |
| 2013 Q4 | -5.03 Billion KRW | -150.11% |
| 2013 Q2 | 8.07 Billion KRW | 4.68% |
| 2012 Q4 | 11.49 Billion KRW | -0.33% |
| 2012 FY | 51.64 Billion KRW | 0.0% |
| 2012 Q3 | 11.53 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| iNtRON Biotechnology, Inc. | 9.58 Billion KRW | -347.559% |
| BINEX Co., Ltd. | 154.82 Billion KRW | 72.291% |
| Bioneer Corporation | 263.23 Billion KRW | 83.703% |
| Anterogen.Co.,Ltd. | 6.5 Billion KRW | -559.983% |
| MEDIPOST Co., Ltd. | 68.64 Billion KRW | 37.502% |
| CrystalGenomics, Inc. | 4.87 Billion KRW | -779.351% |
| Helixmith Co., Ltd | 4.2 Billion KRW | -921.047% |
| Chabiotech Co.,Ltd. | 953.95 Billion KRW | 95.503% |
| Medy-Tox Inc. | 221.12 Billion KRW | 80.599% |
| Peptron, Inc. | 3.34 Billion KRW | -1183.72% |
| Amicogen, Inc. | 159.9 Billion KRW | 73.171% |
| Genexine, Inc. | 4.42 Billion KRW | -869.148% |
| HLB Therapeutics Co.,Ltd. | 53.74 Billion KRW | 20.184% |
| LegoChem Biosciences, Inc. | 34.14 Billion KRW | -25.64% |
| ALTEOGEN Inc. | 96.52 Billion KRW | 55.554% |
| PharmaResearch Co., Ltd. | 261.01 Billion KRW | 83.564% |
| SillaJen, Inc. | 3.93 Billion KRW | -988.969% |
| JETEMA, Co., Ltd. | 58.71 Billion KRW | 26.936% |
| OliX Pharmaceuticals,Inc | 17.06 Billion KRW | -151.406% |
| Genomictree Inc. | 3.41 Billion KRW | -1155.133% |
| MedPacto, Inc. | - KRW | -Infinity% |
| D&D Pharmatech | 18.67 Billion KRW | -129.697% |
| EASY BIO,Inc. | 165.38 Billion KRW | 74.06% |
| GI Innovation, Inc. | 5.31 Billion KRW | -706.576% |